Active Start-Ups

Business Snapshot
The company is commercializing a treatment for amblyopia (lazy eye) based on a game platform developed in partnership with UBISOFT

Target Market
Amblyopia treatment

Intellectual Property
Issued US and European patents

Founders
Joseph Koziak, Robert Derricotte

Category:
Published on: 10 Oct 2019

Business Snapshot
The company manufactures microfluidic platforms for the diagnostics and biomedical research markets. The technology increases the standardization, precision and reproducibility of cell assays and can be integrated with sensors and electronic devices in order to acquire, store and manage data at a single cell level.

Target Markets
Diagnostics and biomedical research markets

Intellectual Property
In prosecution.

Founder
Margaret Magdesian

Category:
Published on: 10 Oct 2019

Business Snapshot
Company produces/distributes proprietary FANA oligonucleotides with unique advantages in industrial scale quantities based on proprietary oligonucleotide production methods.

Target Markets
FANA technology can be used for discovery, translation, and potentially for therapeutic development. Company is working with collaborators for therapeutic development for a wide spectrum of genetic diseases as well as making RNA silencing and regulation available to biomedical researchers across the globe.

Category:
Published on: 10 Oct 2019

Business Snapshot
Using a unique drug discovery platform to identify and develop novel inhibitors for treatment of various inflammation diseases, such as multiple sclerosis. This platform includes several in-vitro and in-vivo models for efficient drug screening and confirmation of potential lead candidates.

Target Markets
Inflammation (neuro-inflammation in particular)

Intellectual Property
Granted in Europe, in prosecution elsewhere.

Founder
Philippe Gros

Category:
Published on: 10 Oct 2019

Business Snapshot
Developing a drug that is an alternative to testosterone replacement therapy. The drug stimulates the body's own production of testosterone rather than using synthetic hormones and steroids.

Target Markets
Testosterone market (men's health)

Intellectual Property
In prosecution in the United States, Europe, India, and Australia.

Founders
Vassilios Papadopoulos, Costas Karatzas, Duane Knight, Jr., Richard Schell

Category:
Published on: 10 Oct 2019

Business Snapshot
Company possesses technology that addresses the problem of dental implant infections and failure, using innovative and proprietary inorganic crystalline hydrogels.

 

Target Markets
Dental and implants.

Intellectual Property
Patents pending in Canada, US, Europe.

Founders
Faleh Marino Tamimi, Ashwaq Al-Hashedi

Category:
Published on: 10 Oct 2019

Business Snapshot
Kanyr has proprietary data on their mechanism of action and a proprietary small molecule lead compound inhibitor allowing for the targeting of phosphatases of regenerating liver (PRLs) through a newly identified co-oncogenic partner.

Target Markets
Immunotherapy (cancer).

Intellectual Property
In prosecution in Canada, US, Europe, Japan, China.

Founder
Michel Tremblay

Category:
Published on: 10 Oct 2019

Business Snapshot
Company has developed a clinical stage, orally-active drug candidate with the potential to modulate the immuno-inflammatory response in cystic fibrosis patients.

Target Markets
Cystic fibrosis

Intellectual Property
Patents around the world

Founder
Danuta Radzioch, Radu Pislariu

Category:
Published on: 10 Oct 2019

Business Snapshot
Develop and market develop novel gene-delivering medical devices that improve human health.

Target Markets
Gene-delivering coronary stent, gene-delivering film-dressing to promote and accelerate wound healing (e.g. for diabetic foot ulcers), gene-delivering sutures and gene-delivering creams to prevent scar tissue formation.

Intellectual Property
Patent in the US and pending in Canada.

Founder
Satya Prakash

Category:
Published on: 10 Oct 2019

Business Snapshot
Mimetogen Pharmaceuticals is a clinical stage biotechnology company focused on developing the use of peptidomimetics as a novel approach to treating ophthalmic diseases.

Target Markets
Dry eye

Intellectual Property
Patents around the world

Founder
Uri Saragovi

Category:
Published on: 10 Oct 2019

Business Snapshot
Two user-focused platforms, FORECASTER and VIRTUAL CHEMIST, are used for drug discovery, metabolism prediction, combinatorial chemistry, and asymmetric catalyst design.

Target Markets
Pharmaceutical companies with drug discovery capabilities and fine chemical manufacturers.

Intellectual Property
Proprietary software is copyrighted.

Founders
Nicolas Moitessier, Eric Therrien

Category:
Published on: 9 Oct 2019

Business Snapshot
Develop a polymeric nano-delivery vehicle for therapeutics like small interfering RNA (siRNA), pDNA (plasmid DNA), shRNA (short hairpin RNA), antisense oligonucleotides (ASOs), chemotherapeutic drugs and small molecules. The delivery vehicle developed (NORAfecta) is a platform technology that can cater its suitability towards different applications, such as targeting cancer and neurodegenerative diseases.

Target Markets
Cancer, CNS disorders.

Category:
Published on: 9 Oct 2019

Business Snapshot
The company manufactures a low temperature plasma device for biomedical applications. For cancer applications, the technology will kill cancer cells while avoiding the surrounding healthy tissue.

Target Markets
Oncology, specifically breast cancer.

Intellectual Property
Granted patents in the US and Canada

Founders
Valérie Léveillé

Category:
Published on: 9 Oct 2019

Business Snapshot
The company is leveraging nanotechnology to develop smart, programmable reagents that address longstanding challenges in multiplexed protein quantification.

Target Markets
Research and pharmaceutical.

Intellectual Property
Patent application in the US, PCT patent application

Founders
Milad Dagher, David Juncker

Category:
Published on: 9 Oct 2019

Business Snapshot
The company manufactures high performance semiconductor sensors, frequency and timing devices. In addition, it has incorporated its pressure sensor in a wireless tissue monitoring device to address the Acute Compartment Syndrome, (ACS). ACS is a major limb-threatening muscle complication that can develop after a fracture or trauma.

Target Markets
Acute Compartment Syndrome and other medical pressure sensing applications

Intellectual Property
In prosecution.

Category:
Published on: 9 Oct 2019

Pages